MyMyelomaTeam

What are the statistics on ICANS, neurological issues, and survival after Carvykti CAR T-cell therapy for high-risk multiple myeloma?

Unfortunately, the available information doesn't include specific statistics on ICANS (immune effector cell-associated neurotoxicity syndrome) or detailed neurological side effects Show Full Answer

What are the statistics on ICANS, neurological issues, and survival after Carvykti CAR T-cell therapy for high-risk multiple myeloma?

Unfortunately, the available information doesn't include specific statistics on ICANS (immune effector cell-associated neurotoxicity syndrome) or detailed neurological side effects specifically related to Carvykti CAR T-cell therapy.

What we do know is that Carvykti (ciltacabtagene autoleucel) is the second CAR T-cell therapy approved for multiple myeloma. CAR T-cell therapy in general can lead to side effects, and more intensive treatments often come with risks like fatigue, nausea, infections, or neuropathy (nerve damage).

For high-risk multiple myeloma specifically, certain genetic features can impact how well treatments work and affect survival outcomes. People with high-risk cytogenetic features tend to have shorter survival times because these mutations can make cancer more resistant to treatment.

It's important to discuss these specific concerns with your oncology team, as they can provide personalized information about your treatment risks and expected outcomes based on your individual situation. They can also help manage any side effects that may occur during or after CAR T-cell therapy.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

Stage 2 Multiple Myeloma Prognosis: Fear, Hope, and Understanding Survival Rates

What Is the Life Expectancy With Relapsed/Refractory Myeloma?